Biotin-thiamine responsive basal ganglia disease in the era of COVID-19 outbreak diagnosis not to be missed: A case report.

The differential diagnosis of BTRBGD is often difficult especially regarding post-viral acute necrotizing encephalitis and other neurometabolic disorders (e.g., mitochondrial diseases, glutaric aciduria type I, methyl-malonic acidemia, 3-methyl-glutaconic aciduria) with similar MRI brain findings and triggering factors [12] , furthermore early molecular identification is extremely significant because early treatment with high doses of biotin and thiamine can stop further basal ganglia damage and put an end to the development of neurological symptoms [13] .

also in 7,787 other papers